Pulmonary Hypertension

FDA Approves New Inhalation Device for Use With Tyvaso

By October 23, 2017

The new device, TD-300/A, features a more ergonomic design with a single-button operation, an intuitive user interface to adjust breath counts, an internal, rechargeable battery, and a color graphical display that guides patients through the inhalation process and shows the time since last treatment.

FDA Approves Tracleer for the Treatment of Pediatric PAH

By September 06, 2017

The new 32mg tablet for oral suspension marks the first FDA-approved drug for pediatric PAH.

Uptravi Labeling Updated with New Contraindication, Drug Interactions

By July 25, 2017

Studies have shown that concomitant administration with gemfibrozil doubled exposure to selexipag and increased exposure to the active metabolite by approximately 11-fold.

Trevyent NDA Submitted for Pulmonary Arterial Hypertension

By July 06, 2017

Trevyent contain treprostinil, a vasodilatory prostacyclin analogue. It works primarily through vasodilation of pulmonary and systemic arterial vascular beds, and inhibition of platelet aggregation.

More Intensive Alveolar Strategy May Benefit Cardiac Sx Patients

March 23, 2017

The mean and median pulmonary complications score was 1.8 and 1.7, respectively, for the intensive recruitment strategy group, compared with 2.1 and 2.0, respectively, for the moderate strategy group.

Food for Thought: Clearing Up the Heart Health Hype

By March 03, 2017

The team reviewed the latest research behind popular food trends to create an evidence-based prescription to provide clinicians with a quick guide to relay to patients in a clinical setting.

Inpatient vs. Outpatient Care for Pulmonary Embolism

February 07, 2017

For patients with hemodynamically stable pulmonary embolism (PE), outpatient management is associated with a lower rate of adverse events, according to research published online January 20 in the Journal of Thrombosis and Haemostasis.

FDA Grants Orphan Drug Status to Novel PAH Treatment

By November 17, 2016

Reviva announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation for RP5063, its lead development product for the treatment of pulmonary arterial hypertension (PAH).

Pre-Treating RBCs With Nitric Oxide May Reduce Transfusion Adverse Effect

By November 07, 2016

A new study published in Anesthesiology has found that exposing red blood cells to the gas nitric oxide may reduce pulmonary hypertension associated with transfusion of red blood cells.

Long-Term Cardiovascular Outcomes Unknown with CPAP Use

August 31, 2016

While treatment with continuous positive airway pressure (CPAP) reduces sleep apnea symptoms, it does not lower users' long-term odds for cardiovascular events, according to a study published online in the New England Journal of Medicine.

IVCF Use Has Increased for Elderly Pulmonary Embolism Patients

March 01, 2016

The use of inferior vena caval filters (IVCFs) for pulmonary embolism (PE) increased from 1999 through 2010, according to research published in the March 8 issue of the Journal of the American College of Cardiology.

Pulmonary Artery Pressure-Guided Tx Cuts Hospitalizations

February 19, 2016

Ambulatory pulmonary artery (PA) pressure-guided management of heart failure patients is more effective in reducing heart failure hospitalizations than management of patient clinical signs/symptoms alone, according to a study published online February 10 in JACC: Heart Failure.

Inhibition of mTOR Restores Corticosteroid Sensitivity in COPD

January 22, 2016

Inhibition of mammalian target of rapamycin (mTOR) by rapamycin restores corticosteroid sensitivity in patients with chronic obstructive pulmonary disease (COPD), according to a study published in the American Journal of Respiratory

Impact of T2DM Meds on Heart Failure Hospitalization Explored

January 19, 2016

For patients with type 2 diabetes, there is no association between hospitalization for heart failure and treatment with dipeptidyl peptidase-4 inhibitors (DPP-4is) versus sulfonylureas (SUs) or treatment with saxagliptin versus sitagliptin.

Uptravi Approved for Pulmonary Arterial Hypertension

By December 22, 2015

The Food and Drug Administration (FDA) has approved Uptravi (selexipag; Actelion) tablets for the treatment of adults with pulmonary arterial hypertension (PAH).

Ubenimex Granted Orphan Drug Status for PAH

By November 30, 2015

The Food and Drug Administration (FDA) has granted Orphan Drug designation to ubenimex (Eiger) for the treatment of pulmonary arterial hypertension (PAH).

First Guidelines for Pediatric Pulmonary Hypertension Issued

November 04, 2015

New guidelines address classifying the different types of disease, approved treatment methods

New Combo for PAH Gains FDA Approval

By October 05, 2015

Gilead Sciences announced that the Food and Drug Administration (FDA) has approved Letairis (ambrisentan) in combination with tadalafil for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1).

Exercise Appears Safe, Beneficial for Patients With Pulmonary HTN

September 14, 2015

Exercise has a positive effect on several measures of heart function as well as overall quality of life for patients with pulmonary hypertension, according to research published recently in Circulation: Heart Failure.

Letairis/Tadalafil Combo Demonstrates Efficacy for Pulmonary HTN

By August 27, 2015

Gilead Sciences announced positive results from the AMBITION study, a Phase 3/4 trial of first-line combination therapy with Letairis (ambrisentan) and tadalafil in patients with WHO/NYHA functional class II and III pulmonary arterial hypertension (PAH).

Six-Minute Walk Test Could Predict Pulmonary HTN

July 21, 2015

The six-minute walk (6MW) stress echocardiography test could be prognostic for development of pulmonary hypertension (PH) in connective tissue disease (CTD).

Pulmonary HTN Reported With Proglycem in Newborns, Infants

By July 16, 2015

The Food and Drug Administration (FDA) has issued a warning that pulmonary hypertension has been reported in infants and newborns treated with Proglycem (diazoxide; Teva) for low blood glucose.

Specific Biomarkers ID Cardiac Dysfunction, Mortality Risk in HIV

July 09, 2015

Specific biomarkers correlate with cardiovascular dysfunction and all-cause mortality among HIV-infected individuals.

Increasing Healthcare Burden for Pediatric Pulmonary HTN

July 07, 2015

There is an increasing health care burden associated with morbidity and mortality of pediatric pulmonary hypertension (PH), according to a study published in Pediatrics.

Significant Number of SLE Patients May Have Pulmonary HTN

June 22, 2015

About 8 percent of patients with systemic lupus erythematosus (SLE) have pulmonary hypertension (PH), and serum uric acid (UA) has reasonable accuracy for predicting PH.

6-Minute Walk Test Could Predict Pulmonary HTN Outcomes

June 03, 2015

For patients with pulmonary hypertension associated with heart failure and preserved ejection fraction (PH-HFpEF), the six-minute walk distance (6-MWD) test could independently predict outcome.

SSRI Use in Late Pregnancy Linked to PPHN, But Risk is Small

By June 02, 2015

While a new study appearing in the Journal of the American Medical Association suggests that use of antidepressants in late pregnancy may be associated with an increased risk of persistent pulmonary hypertension of the newborn (PPHN), the absolute risk is small and the risk increase appears to be less than previous studies have suggested.

Orphan Status Granted to Investigational Pulmonary Arterial Hypertension Drug

By March 18, 2015

The Food and Drug Administration (FDA) has granted Orphan Drug designation to tacrolimus (SPI-026; Selten Pharma) for the treatment of pulmonary arterial hypertension.

Cardioprotection with an Erectile Dysfunction Drug? Study Says Yes

October 21, 2014

Phosphodiesterase type 5 inhibitors (PDE5i) have been used to treat erectile dysfunction and pulmonary arterial hypertension but could long-term, continuous administration of these agents provide effective cardiac protection?

FDA: Asthma Drug May Increase Risk of CV, Cerebrovascular Events

September 26, 2014

The Food and Drug Administration (FDA) is warning about a slightly increased risk of cardiovascular and cerebrovascular events among patients being treated with Xolair (omalizumab; Genentech and Novartis) for asthma compared to those not treated with Xolair.